Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Circ Heart Fail. Author manuscript; available in PMC 2010 September 1.
Published in final edited form as:
PMCID: PMC2756764

Lipoprotein-Associated Phospholipase A2 and Risk of Congestive Heart Failure in Older Adults: the Cardiovascular Health Study

Takeki Suzuki, MD, MPH,1 Cam Solomon, PhD,2 Nancy Swords Jenny, PhD,3 Russell Tracy, PhD,3 Jeanenne J Nelson, PhD,4 Bruce M. Psaty, MD, PhD,5 Curt Furberg, MD, PhD,6 and Mary Cushman, MD, MSc1,3



Inflammation may be an etiologic factor in congestive heart failure (CHF). Lipoprotein associated phospholipase A2 (Lp-PLA2) is an inflammation marker associated with vascular risk. One previous study showed an association of Lp-PLA2 activity with CHF risk, but there were only 94 CHF cases and Lp-PLA2 antigen, which is available clinically in the US, was not measured.

Methods and Results

We measured baseline Lp-PLA2 antigen and activity in 3991 men and women without baseline CHF or cardiovascular disease, participating in the Cardiovascular Health Study, a prospective observational study of adults ≥65 years old. Cox proportional hazards models adjusted for age, sex, clinic site, race, LDL and HDL cholesterol, body-mass index, systolic and diastolic blood pressure, hypertension, smoking status, pack-years and diabetes were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident CHF. Further models adjusted for coronary disease events during follow up and C-reactive protein (CRP). 829 participants developed CHF over 12.1 years. Adjusted HRs for CHF with Lp-PLA2 in the fourth compared to first quartile, were 1.44 (CI 1.16–1.79) for Lp-PLA2 antigen and 1.06 (CI 0.84–1.32) for activity. Adjustment for incident coronary disease attenuated the HR for Lp-PLA2 antigen to 1.26 (CI 1.02–1.57), adjustment for CRP had minimal impact.


Lp-PLA2 antigen was associated with risk of future CHF in older people, independent of CHF and coronary risk factors, and partly mediated by coronary disease events. Further clinical and basic research is needed to better understand the role of Lp-PLA2 in CHF.


Congestive heart failure (CHF) is a major public health problem in the United States. Approximately 5 million patients have CHF and 550,000 are newly diagnosed each year.1 Accumulating evidence supports that inflammation is an underlying pathophysiology of CHF.2, 3 Various inflammation markers such as C-reactive protein (CRP) and interleukin (IL)-6 are increased in patients with CHF.46 CRP and IL-6 have been shown to be associated with incident CHF.79

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase (PAF-AH), is an inflammation marker used for cardiovascular risk assessment.10 It is synthesized by monocytes and macrophages, and, in the circulation, is bound to LDL.11, 12 Lp-PLA2 has proinflammatory properties through hydrolyzing oxidized phospholipids generating lysophosphatidylcholine and oxidized fatty acids.13, 14 Lp-PLA2 is strongly expressed in advanced coronary plaques suggesting a potential role in promoting plaque instability.15 However, Lp-PLA2 may also play an anti-inflammatory role through inhibition of PAF.16 Lp-PLA2 can be measured using an activity assay or a commercially available antigenic (mass) assay17 and the antigen and activity were measured in previous epidemiological studies.18, 19 In a previous study from the Cardiovascular Health Study (CHS), Lp-PLA2 activity and antigen were not correlated (r = 0.51), but this modest association points out the importance of considering both measures.20 Recently, a U.S. expert panel published a document on the clinical use of Lp-PLA2 in cardiovascular disease.21

Several epidemiological studies reported that higher Lp-PLA2 is a risk marker for coronary heart disease (CHD)2228 and ischemic stroke.22, 26 One study is available which reported an association of Lp-PLA2 activity with risk of CHF29, but there were less than 100 cases and Lp-PLA2 antigen, which is available clinically in the U.S., was not measured. Thus, whether Lp-PLA2 antigen or activity are a risk factor for CHF is not clear. We examined the association of both Lp-PLA2 antigen and activity with risk of future CHF in the CHS.



The Cardiovascular Health Study (CHS) is a prospective population-based observational study of older adults ≥65 years old at baseline to evaluate risk factors for the development and progression of cardiovascular disease (CVD). The design, rationale and examination details have been described elsewhere.30 Briefly, participants were randomly selected from Medicare eligibility lists in four field centers: Forsyth County, North Carolina; Sacramento County, California, Allegheny County, Pennsylvania, and Washington County, Maryland. An initial primarily white cohort of 5201 was recruited between 1989 and 1990 and an additional 687 African-Americans (minority cohort) were recruited in 1992 and 1993. Persons were ineligible for participation if they were receiving active treatment for cancer, were wheelchair-bound or institutionalized, or were unable to participate in the examination. Comprehensive examinations and interviews were performed annually. The study was approved by institutional review boards at each site. Informed consent was obtained from all subjects.

Self-reported health behaviors, medical history, anthropometric measures, current medication use, seated blood-pressure readings, electrocardiography recordings, and fasting blood chemistry measures were obtained at baseline for both cohorts. Common carotid intima-media thickness (IMT) was measured at baseline in a standard manner as previously described.31 In previous CHS reports, IMT was an independent predictor of CHF6 and Lp-PLA2 was significantly higher in participants with higher IMT.20 Echocardiograms were obtained at baseline for the original cohort and again for members of both cohorts in 1994 to 1995. All participants in the original and minority cohorts were included in the primary analysis, except for 80 participants with baseline history of CHF, 115 with valvular heart disease by echocardiography (92 with aortic stenosis and 23 with severe mitral regurgitation), and 1190 with baseline CVD. Baseline CVD was defined as having one of the following at baseline: history of myocardial infarction, angina, stroke, transient ischemic attack, claudication, coronary artery bypass surgery, leg artery bypass, carotid endarterectomy, coronary angioplasty, or lower extremity angioplasty. Baseline CVD and CHF were adjudicated by a combination of self report of physician diagnosis as well as review of medical records.32 Secondary analysis was performed among participants with baseline CVD.

Laboratory Methods

Phlebotomy was performed on the morning of enrollment after 8–12 hours fast.30 Fibrinogen, total and HDL cholesterol, triglyceride, glucose and creatinine were measured at the central laboratory as previously reported.33 LDL cholesterol was calculated for those with triglycerides <400 mg/dL. CRP was measured by an in-house validated high-sensitivity enzyme-linked immunosorbent assay (ELISA).34 Interleukin-6 (IL-6) was measured by high-sensitivity ELISA (R&D Systems, Minneapolis, MN, USA).35 The interassay coefficients of variation were 6% for CRP and 7% for IL-6.34, 35 Elevated CRP was defined as >3.0 mg/L corresponding to the “high risk category” in the American Heart Association/Centers for Disease Control (AHA/CDC) consensus statement.36 Elevated IL-6 and fibrinogen were defined as values in the top tertile of the distribution (≥2.04 pg/mL and >338 mg/dL, respectively).

Plasma Lp-PLA2 antigen (or “mass”) was determined at the Laboratory for Clinical Biochemistry Research (University of Vermont, Burlington, VT) using a commercially available enzyme-linked immunosorbant assay (ELISA) kit (second generation PLAC Test; diaDexus Inc., South San Francisco, CA, USA). Plasma Lp-PLA2 activity was measured at GlaxoSmithKline (Research Triangle Park, NC) by high throughput radiometric assay using a tritium-labeled form of platelet activating factor [3H PAF] as substrate in a 96-well microplate, as previously described.17 The interassay coefficients of variation were 6.3 % for Lp-PLA2 antigen and 7.5 % for Lp-PLA2 activity.

Adjudication of Incident Congestive Heart Failure Events

Our outcome was incident CHF, which was assessed and validated as previously reported.37, 38 Subjects were interviewed every 6 months and follow-up examinations were conducted annually at each study center until May 31, 1998, after which telephone follow up continued. Self-report of a physician diagnosis of CHF was confirmed by review of medical records, with validation requiring a constellation of symptoms (shortness of breath, fatigue, orthopnea, paroxysmal nocturnal dyspnea), physical signs (edema, pulmonary rales, gallop rhythm, displaced left ventricular apical impulse), chest X-ray results (cardiomegaly and pulmonary edema), and treatment of CHF using diuretic agents, digitalis, or vasodilators (nitroglycerin, hydralazine, or angiotensin-converting enzyme inhibitors). The CHS Events Committee adjudicated the index event of congestive heart failure by reviewing all pertinent data on hospitalization or outpatient visits, including history, physical examination, report of chest X-ray, and medication use. This analysis includes validated events through June 30, 2003.

Statistical Analysis

Baseline characteristics were compared between those who developed CHF and those who didn’t by using chi square tests for discrete values and t tests for continuous data. Lp-PLA2 antigen or activity was divided into quartiles (Quartile1–4, 1 being the lowest, 4 being the highest values) based on sex (men and women) and race (African American and non-African American).

Kaplan-Meier curves with the endpoint of CHF were constructed based on Lp-PLA2 antigen or activity quartiles. A log-rank test was performed to examine differences among the four groups. The associations of these categories of Lp-PLA2 antigen or activity level with incident CHF were assessed using Cox proportional hazards models. Hazard ratios (HRs) and 95% confidence intervals (CIs) for incident CHF were calculated for each Lp-PLA2 quartile compared to the 1st quartile. Models were first adjusted for age, sex, clinic site and race. Additional adjustments included LDL and HDL cholesterol, body-mass index, systolic and diastolic blood pressure, hypertension status, smoking status and pack-years, and diabetes status. Incident validated CHD was added to the model as a time-dependent covariate to assess mediation. Incident CHD was defined as incident MI, angina, angioplasty, coronary artery bypass surgery, or CHD death. Additional variables were added individually to evaluate potential biological pathways of Lp-PLA2 and incident CHF: baseline serum creatinine, statin and aspirin use, CRP, IL-6, left ventricular (LV) mass by electrocardiography39, and common carotid IMT. In secondary analysis, we replicated the above models among participants with baseline CVD. We did not adjust for incident CHD in secondary analysis since these participants had already had baseline CHD.

Stratified analyses were subsequently performed on the basis of sex and race (African American and non-African American). In addition, since it has been reported that Lp-PLA2 was more strongly associated with vascular events in those with low LDL cholesterol and in those subjects, those with both elevated Lp-PLA2 and CRP were at the greatest risk for CHD22, we evaluated incident CHF stratified by the levels of LDL (above or below median), HDL (above or below median), and CRP (above or below 3 mg/L).

To evaluate the combined predictive value of Lp-PLA2 and other inflammation markers for incident CHF, participants were cross-classified by Lp-PLA2 and inflammation markers (CRP >3 mg/L, and IL-6 and fibrinogen in tertiles) and interactions between Lp-PLA2 and these inflammation markers were assessed by calculating the relative excess risk due to interaction (RERI)40, 41, as well as the RERI%, defined as the proportion of disease related to Lp-PLA2 and the inflammation marker, either singly or in combination, attributable to their interaction. The Delta method was used to calculate P-values and 95% confidence intervals used to assess significance of the RERI.

Statistical analyses were performed at the Cardiovascular Health Study Coordinating Center using Stata, Release 10 (Stata Co, College Station, Texas).


Baseline characteristics of the 3991 participants are shown in Table 1. There were 829 incident CHF cases over 12.1 years of follow-up (incidence rate of 19.1 per 1000 person-years). Those who developed CHF were older, more likely to be male, and to have diabetes, hypertension and greater LV mass. Smoking was relatively uncommon and was similar between the two groups. Baseline Lp-PLA2 antigen and activity, along with other inflammation markers, were higher in those who developed CHF. There were 1190 participants with baseline CVD evaluated in secondary analyses. Patterns of association of baseline risk factors with CHF were similar to those without baseline CVD (data not shown).

Table 1
Baseline Characteristics by Incident CHF Status, Cardiovascular Health Study*

Associations between Lp-PLA2 Antigen/Activity and Incident CHF

Kaplan-Meier curves for time to CHF by Lp-PLA2 antigen or activity quartiles are shown in Figure 1. Those with the highest Lp-PLA2 antigen were more likely to develop CHF during follow-up, with the 10-year cumulative incidence rate ranging from 11.7 per 1000 person-years in the first quartile to 19.5 per 1000 person-years in the 4th quartile (P=0.0001) for difference among groups. There were no significant differences in CHF incidence among the quartiles of Lp-PLA2 activity.

Figure 1Figure 1
Kaplan-Meier curves for time to CHF by Lp-PLA2 antigen (1A) or activity (1B) quartiles

The HRs of CHF for each quartile of Lp-PLA2 antigen and activity, compared with the first quartile, are shown in Table 2. Lp-PLA2 antigen in the top three quartiles, but not activity, were associated with increased risk of CHF, with gradually increasing risk by quartile for Lp-PLA2 antigen. The HR for Lp-PLA2 antigen in the top quartile was 1.44 (95% CI 1.16–1.79) and that for Lp-PLA2 activity was 1.06 (0.84–1.32) after adjustment for LDL and HDL cholesterol, body mass index, systolic and diastolic blood pressure, hypertension status, smoking status and pack-years, and diabetes status. When incident CHD was added to the model as a time-dependent covariate, the HRs for Lp-PLA2 antigen in the top three quartiles were reduced, but remained significant with about a 25% increased risk for values above the median. Additional adjustment for other covariates, including common carotid IMT, had minimal impact on associations except IL-6 or LV mass, which slightly accentuated the HRs for Lp-PLA2 (Table 2).

Table 2
Hazard Ratios and 95% CIs for Lp-PLA2 Antigen/Activity Quartiles and Incident CHF

Stratified Analyses

Figure 2 shows results of stratified analyses for Lp-PLA2 antigen and risk of CHF. Lp-PLA2 antigen in the top quartile was associated with incident CHF in women (HR 1.46, 95% CI 1.10–1.94) but not men (HR 1.08, 95% CI 0.77–1.51). The association between Lp-PLA2 antigen and incident CHF was slightly larger in non-African Americans (HR 1.30, 95% CI 1.03–1.65) than African-Americans (HR 1.20, 95% CI 0.68–2.14). Associations between Lp-PLA2 antigen and CHF were stronger in those with LDL below median and with HDL above median. The association was stronger in those with elevated CRP. However, none of these associations were significantly different between strata.

Figure 2
Hazard Ratios for Lp-PLA2 Antigen in the Fourth versus First Quartile Stratified by Other Risk Factors*

Interaction between Lp-PLA2 and Other Inflammation Markers

The joint associations of Lp-PLA2 antigen and inflammation markers, adjusted for risk factors and interval incident CHD, are shown in Table 3. In general the inflammation markers had larger associations than Lp-PLA2 with incident CHF. The relative excess risks due to interaction (RERI) between Lp-PLA2 antigen and inflammation markers were calculated. Considered jointly, the risk of CHF was 13 to 16% higher than expected by the separate additive effects of Lp-PLA2 antigen and other inflammation markers. For example, those with high Lp-PLA2 antigen (top tertile) and high CRP (≥ 3mg/L) had a higher risk of CHF compared to those without either risk factor (HR 2.05, 95% CI 1.68–2.51). When considering interaction additively, a significant proportion of CHF risk, 13.9% (95% CI 6.3%–21.6%), was related to the combination of high levels of CRP and Lp-PLA2 antigen.

Table 3
Combined Association of Lp-PLA2 Antigen and inflammation markers on Risk of CHF

Secondary Analysis in Participants with Baseline CVD

There were 440 incident CHF cases among 1190 participants with baseline CVD and no baseline CHF over 12.1 years of follow-up (incidence rate of 44.1 per 100 person-years). In these participants, the association of Lp-PLA2 antigen with incident CHF was similar to the association in those without baseline CVD after adjustment for risk factors (HR 1.36, 95% CI 1.02–1.83, Table 4). After adjustment for individually for serum creatinine, CRP, IL-6, or LV mass, the association between Lp-PLA2 antigen and incident CHF was modestly smaller and no longer statistically significant. The HR of incident CHF for Lp-PLA2 activity was similar to that of Lp-PLA2 antigen, with adjustment for age, sex, clinic site, and race.

Table 4
Hazard Ratios and 95% CIs for Incident CHF by Lp-PLA2 Quartiles in Subjects with baseline CVD and no CHF


The main finding of this study was that Lp-PLA2 antigen, but not activity, was associated with increased 12-year risk of CHF in older people without CVD or CHF at baseline, even after adjustment for interval development of CHD, which appeared to mediate part of this association. Adjustment for other CHF risk factors, including CVD risk factors, creatinine, common carotid IMT, or other inflammation markers had minimal impact on this association. In contrast, Lp-PLA2 activity was not associated with risk of incident CHF, except in participants with baseline CVD. There was modest complementary information in CHF risk prediction using combinations of elevated Lp-PLA2 and other inflammation risk markers CRP, IL-6 and fibrinogen.

Previous epidemiologic studies have demonstrated associations between Lp-PLA2 and risk of CVD 2227. For CHF, the Rotterdam Study reported a hazard ratio of 2.33 for Lp-PLA2 activity in the 4th versus 1st quartile with risk of CHF over 6.7 years (95% CI 1.21–4.49)29, but there were less than 100 CHF cases and Lp-PLA2 antigen, which is available clinically in the U.S., was not measured. In our study Lp-PLA2 antigen, but not activity, was associated with incident CHF, in an analysis involving 829 cases. The different findings between the studies could be due to differences in population characteristics and study design. Our cohort was older, had a higher CHF incidence rate, and a larger sample size and number of incident cases compared with the Rotterdam Study. Prior analyses in CHS showed that Lp-PLA2 antigen and activity were associated with risk of myocardial infarction, while antigen but not activity was associated with stroke risk (Jenny et al, manuscript submitted). Disparate findings for antigen and activity assays may reflect assay design issues, pre-analytical factors such as differences in biovariability, complex biology of Lp-PLA2, and heterogeneity of congestive heart failure and stroke as clinical syndromes. These findings may also relate to the modest, not high, correlation between antigen and activity or non-linear relationship between the two.20 In the CARDIA study, Lp-PLA2 antigen was independently associated with calcified coronary plaque, while Lp-PLA2 activity was not.18 Along with our findings, these results suggest Lp-PLA2 antigen might be more associated with atherosclerosis than activity is. In contrast to our primary analysis involving participants without baseline CVD, analyses in those with baseline CVD showed associations of both Lp-PLA2 antigen and activity with incident CHF. This is compatible with our prior observations of associations of both analytes with MI and suggests that both analytes reflect biologies related to CHF associated with atherosclerosis. This may suggest that both analytes represent biologies reflecting a similar role in those with baseline atherosclerosis.

In stratified analyses, associations between Lp-PLA2 antigen and CHF were stronger in non-African Americans, with LDL below median, and HDL above median. Our results agree with a previous study which showed that the association between Lp-PLA2 and coronary heart disease risk was stronger in those with LDL below median22, but this was not observed in CHS for vascular outcomes (Jenny et al, manuscript submitted). This difference could be due to differing results with different outcomes, different population characteristics or that it is a chance finding. Inconsistent subgroup findings across studies require further evaluation and may be pursued using individual-level meta-analysis.42

The pathophysiology explaining an association of Lp-PLA2 with CHF may relate to Lp-PLA2 as an inflammation marker.2, 3 Lp-PLA2, along with LDL particles, is proinflammatory by releasing lysophosphatidylcholine and oxidized nonesterified fatty acids. Our models evaluating biological pathways of Lp-PLA2 and development of CHF suggested that adjustment for kidney function and other inflammation markers had minimal impact on the association between Lp-PLA2 and CHF, consistent with the weak correlations of Lp-PLA2 with renal function and inflammation markers.20 In previous studies, Lp-PLA2 was related to different aspects of inflammation than CRP or IL-6.18, 27 Our findings suggest a hypothesis that Lp-PLA2 may represent a novel inflammatory pathway in the development of CHF. Further, our study suggests that the association between Lp-PLA2 antigen and incident CHF is minimally mediated by interval changes of coronary heart disease or baseline common carotid IMT. This could be because atherosclerotic burden was not fully accounted for by adjustment for these factors. However, this may mean that an inflammation pathway involving Lp-PLA2 plays an important role in cardiac function independent of atherosclerosis. This may be supported by recent findings that Lp-PLA2 was associated with mortality in a community-based cohort of CHF patients.43 Lastly, there is a Lp-PLA2 inhibitor under investigation. Given the current findings, a Lp-PLA2 inhibitor could be studied in relation to CHF as well as vascular outcomes.

The strengths of our study include measurement of both Lp-PLA2 antigen and activity, its prospective population-based design, bi-ethnic sample, large sample size, long follow-up, and large number of incident CHF cases. Limitations of the study need to be considered. First, institutionalized individuals and those with short life expectancy were excluded. Thus, the sample was a relatively healthy community-dwelling elderly one and our results cannot be extrapolated to others. Second, the relatively low numbers of African Americans resulted in less power for ethnic-specific analyses. Third, adjustment of interval development of coronary heart disease may not account fully for role of atherosclerosis in CHF etiology. We added common carotid IMT to the model and it did not change the association. Residual confounding could be invoked to suggest that the associations of Lp-PLA2 with CHF are not independent of subclinical or clinical vascular disease. Lastly, instability of proteins in long-term storage may lead to underestimates of risk in epidemiology studies, but we anticipate this to play a small role of this issue given the documented stability of other proteins in stored samples.45

In conclusion, Lp-PLA2 antigen was a risk factor for future CHF in older people, independent of CHF risk factors, other inflammation markers, and atherosclerosis measures. The association was partly mediated by occurrence of coronary vascular events. Further clinical and basic research is needed to better understand the pathophysiological role of Lp-PLA2 in the development of CHF.


The authors thank the staff and participants in the Cardiovascular Health Study. A full list of participating CHS investigators and institutions can be found at

Funding Sources

This research was supported by contracts N01-HC-35129, N01-HC-45133, N01-HC-75150, N01-HC-85079 through N01-HC-85086, N01 HC-15103, N01 HC-55222, and U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. Measurement of Lp-PLA2 was supported by GlaxoSmithKline. The sponsors were involved in the design and conduct of the study and approval of the final manuscript.

Funding: NHLBI, GlaxoSmithKline


Journal Subject Codes: [8] Epidemiology, [110] Congestive Heart Failure


Dr. Jeanenne J Nelson is an employee of GlaxoSmithKline. Dr. Mary Cushman has received modest research support and consulting fees from GSK. All other authors have no conflict of interest.


1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O’Donnell C, Kittner S, Lloyd-Jones D, Goff DC, Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–151. [PubMed]
2. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–18. [PubMed]
3. Yndestad A, Kristian DJ, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure--the whys and wherefores. Heart Fail Rev. 2006;11:83–92. [PubMed]
4. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:391–8. [PubMed]
5. Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud AP. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J. 2006;151:845–50. [PubMed]
6. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628–37. [PubMed]
7. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108:2317–22. [PubMed]
8. Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, Witteman JC. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J. 2006;152:514–20. [PubMed]
9. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D’Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–91. [PubMed]
10. Zalewski A, Nelson JJ, Hegg L, Macphee C. Lp-PLA2: a new kid on the block. Clin Chem. 2006;52:1645–50. [PubMed]
11. Karabina SA, Liapikos TA, Grekas G, Goudevenos J, Tselepis AD. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta. 1994;1213:34–8. [PubMed]
12. Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem. 1999;274:7018–24. [PubMed]
13. Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479–87. [PubMed]
14. Snyder F. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta. 1995;1254:231–49. [PubMed]
15. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523–9. [PubMed]
16. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens LS, Zimmerman GA. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 1995;374:549–53. [PubMed]
17. Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2006;26:631–6. [PubMed]
18. Iribarren C, Gross MD, Darbinian JA, Jacobs DR, Jr, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol. 2005;25:216–21. [PubMed]
19. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411–6. [PubMed]
20. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM. Distribution and Correlates of Lipoprotein-Associated Phospholipase A(2) in an Elderly Cohort: The Cardiovascular Health Study. J Am Geriatr Soc. 2008;56:792–9. [PubMed]
21. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006;9:138–43. [PubMed]
22. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–842. [PubMed]
23. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302–6. [PubMed]
24. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137–44. [PubMed]
25. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903–8. [PubMed]
26. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570–5. [PubMed]
27. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148–55. [PubMed]
28. Schmidt EB, Koenig W, Khuseyinova N, Christensen JH. Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis. 2008;196:420–4. [PubMed]
29. van Vark LC, Kardys I, Bleumink GS, Knetsch AM, Deckers JW, Hofman A, Stricker BH, Witteman JC. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam Study. Eur Heart J. 2006;27:2346–52. [PubMed]
30. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263–76. [PubMed]
31. O’Leary DH, Polak JF, Wolfson SK, Jr, Bond MG, Bommer W, Sheth S, Psaty BM, Sharrett AR, Manolio TA. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke. 1991;22:1155–63. [PubMed]
32. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5:270–7. [PubMed]
33. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41:264–70. [PubMed]
34. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52–8. [PubMed]
35. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, Jr, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506–12. [PubMed]
36. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511. [PubMed]
37. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol. 1995;5:278–85. [PubMed]
38. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5:270–7. [PubMed]
39. de Vries SO, Heesen WF, Beltman FW, Kroese AH, May JF, Smit AJ, Lie KI. Prediction of the left ventricular mass from the electrocardiogram in systemic hypertension. Am J Cardiol. 1996;77:974–8. [PubMed]
40. Hallqvist J, Ahlbom A, Diderichsen F, Reuterwall C. How to evaluate interaction between causes: a review of practices in cardiovascular epidemiology. J Intern Med. 1996;239:377–82. [PubMed]
41. Rothman K. Modern Epidemiology. Boston: Little, Brown; 2006.
42. Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Sacco R, Elkind M, Talmud P, Rimm E, Cannon CP, Packard C, Barrett-Connor E, Hofman A, Kardys I, Witteman JC, Criqui M, Corsetti JP, Rainwater DL, Moss AJ, Robins S, Bloomfield H, Collins D, Packard C, Wassertheil-Smoller S, Ridker P, Ballantyne C, Cannon CP, Cushman M, Danesh J, Gu D, Hofman A, Nelson JJ, Thompson S, Zalewski A, Zariffa N, Di AE, Kaptoge S, Thompson A, Thompson S, Walker M, Watson S, Wood A. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil. 2007;14:3–11. [PubMed]
43. Gerber Y, Dunlay SM, Jaffe AS, McConnell JP, Weston SA, Killian JM, Roger VL. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the community. Atherosclerosis. 2008 In press. [PMC free article] [PubMed]
44. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von BC, D’Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172–82. [PubMed]
45. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal Stability of Coagulation, Fibrinolysis, and Inflammation Factors in Stored Plasma Samples. Thrombosis and Haemostasis. 2001;86:1495–500. [PubMed]